Therapeutic Plasma Exchange Market Report 2025

This Therapeutic Plasma Exchange market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The therapeutic plasma exchange market size has grown strongly in recent years. It will grow from $1.47 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to the emergence of immunological diseases, increasing technological advancements, increased awareness and education, expanded indications, and improved understanding of the pathophysiology.

The therapeutic plasma exchange market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to the rising geriatric population, clinical evidence and guidelines, regulatory environment, hospital infrastructure and healthcare investments, healthcare expenditure, and reimbursement policies. Major trends in the forecast period include personalized therapies, integration of automation, collaborative initiatives, and telemedicine integration.

The increasing prevalence of hematological disorders is poised to drive the expansion of the therapeutic plasma exchange market in the future. Hematological disorders, or blood disorders, encompass medical conditions affecting blood and blood-forming tissues such as bone marrow, lymph nodes, and spleen. The rise in these disorders is attributed to factors such as genetic predispositions, environmental influences, and changes in lifestyle. Therapeutic plasma exchange (TPE) is employed in managing hematological disorders by removing pathogenic substances from the plasma, such as autoantibodies in autoimmune hemolytic anemia or immune complexes in thrombotic thrombocytopenic purpura, thus alleviating disease severity and enhancing patient outcomes. For example, in August 2023, as per the Leukemia and Lymphoma Society, a US-based professional organization, the projected number of myeloma diagnoses is expected to increase by approximately 2.3% from 2021 to 2023, rising from 34,920 to 35,730, respectively. Hence, the high prevalence of hematological disorders is fueling the growth of the therapeutic plasma exchange market.

In July 2022, Terumo Blood and Cell Technologies, a US-based technology company, formed a strategic partnership with Eliaz Therapeutics Inc., a US-based medical device company specializing in therapeutic apheresis for inflammatory and kidney-related conditions. This collaboration focuses on addressing acute kidney injury (AKI) and sepsis-induced AKI (S-AKI) by selectively removing the inflammatory protein Gal-3 from blood plasma. The partnership aims to explore novel treatments using Terumo's Spectra Optia Apheresis System and Eliaz Therapeutics' XGal-3 column. Given the high mortality rates associated with AKI, the partnership's initial studies will be conducted in large animals before progressing to human clinical trials. Terumo is known for its expertise in therapeutic apheresis and has previously collaborated on projects targeting conditions such as triple-negative breast cancer and COVID-19.

In July 2022, Discovery Life Sciences, Inc., a US-based provider of biospecimen analysis services, acquired AllCells for an undisclosed amount. This strategic acquisition aims to create a leading global provider of critical starting materials and analytic services, enhancing the development of cell and gene therapies (CGT) across the entire continuum - from discovery to commercialization. AllCells, a US-based company, specializes in providing clinical-grade and research-use primary cell products, including plasma exchange or plasmapheresis services. The acquisition is expected to strengthen Discovery Life Sciences' capabilities in supporting CGT development, positioning the company as a key player in the biotechnology and healthcare sectors.

Major companies operating in the therapeutic plasma exchange market are Medica S.p.A., Fresenius SE and Co. KGaA, Medtronic Plc., Asahi Kasei Corporation, Toray Industries Inc., Baxter International Inc., B Braun Melsungen AG, Terumo Corporation, Kaneka Corporation, Charles River Laboratories, Octapharma AG, Spectral Medical Inc., Nikkiso Co. Ltd., Haemonetics Corporation, Miltenyi Biotec Technology And Trading Co. Ltd., Macopharma SA, Cerus Corporation, Apellis Pharmaceuticals Inc., ImmunoTek Bio Centers LLC, CytoSorbents Corporation, Kawasumi Laboratories America Inc., Japan Medical Supply Co. Ltd.

North America was the largest region in the therapeutic plasma exchange market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the therapeutic plasma exchange market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic plasma exchange market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Therapeutic plasma exchange (TPE) is a medical intervention utilized in the treatment of specific autoimmune diseases and other medical conditions. In this procedure, blood is extracted from the body, the plasma component (the fluid part of blood) is separated from the blood cells, and the blood cells are subsequently reintroduced into the body, often after being mixed with a replacement fluid. This method aids in eliminating harmful substances from the bloodstream, such as autoantibodies or toxins, which are implicated in various diseases.

The primary modalities of therapeutic plasma exchange include therapeutic plasma exchange (TPE) and double-filtered plasmapheresis (DFPP). Therapeutic Plasma Exchange (TPE) is a clinical process that involves removing plasma from the blood and substituting it with a replacement fluid, facilitating the elimination of detrimental substances or excess components. This procedure finds application in diverse medical conditions such as neurological disorders, hematological disorders, renal disorders, metabolic disorders, among others. Various technologies, including centrifugation and membrane separation, are employed in this process, catering to a range of end users such as blood collection centers, hospitals and clinics, transfusion centers, and others.

The therapeutic plasma exchange market research report is one of a series of new reports that provides therapeutic plasma exchange market statistics, including therapeutic plasma exchange industry global market size, regional shares, competitors with a therapeutic plasma exchange market share, detailed therapeutic plasma exchange market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic plasma exchange industry. This therapeutic plasma exchange market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic plasma exchange market consists of revenues earned by entities by providing services such as patient evaluation, treatment planning, medical monitoring, and plasma separation. The market value includes the value of related goods sold by the service provider or included within the service offering. The therapeutic plasma exchange market also includes the sale of plasma separators, replacement fluids, anticoagulants, catheters and access devices, disposable consumables, and monitoring equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.